Navigation Links
Mayo Clinic identifies treatment target for liver cancer recurrence and survival
Date:4/10/2008

ROCHESTER, Minn. -- Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence. But Mayo Clinic Cancer Center, in collaboration with the National Cancer Institute, reports in the April issue of Hepatology that the protein sulfatase 2 (SULF2) may provide one of the keys needed to begin the design of new therapies.

Mayo Clinic Cancer Center leads the field in researching the impact and effect of SULF1, a protein whose normal role is to degrade heparin sulfate proteoglycans -- molecules that are part sugar and part protein. Mayo scientists have found that the protein also helps inhibit tumor growth. Now, Mayo researchers are studying a related gene, SULF2. The role of the SULF2 gene and protein has not been fully defined, but in this study, researchers investigated the effect of SULF2 on liver tumor growth in the laboratory. They found that increased expression of SULF2 enhances cancer cell growth and migration, whereas decreased expression reduces both.

The liver is designed to excrete toxins, and its tumors are no exception, says Mayo Clinic gastroenterologist Lewis Roberts, M.B.Ch.B., Ph.D., the studys primary investigator. Our problem is that the tumors tend to excrete chemotherapeutic agents rather than be affected by them. So we are looking for ways to get around that.

The researchers sought answers by examining a protein related to one they already knew had a role in suppressing liver tumors. SULF1 and SULF2 are similar proteins, but cause opposing results. SULF1 removes sulfate groups that allow growth factors to bind to cells, thus inhibiting growth. The investigators found that SULF2 did the opposite -- it increased binding of a specific growth factor, fibroblast growth factor 2 (FGF2), to tumor cells, and also increased expression of the heparan sulfate proteoglycan glypican 3 (GPC3), which plays an important role in cell division and growth. These findings were confirmed in mouse models.

This discovery indicates if scientists can decrease the levels or activity of SULF2 in a tumor, they might be able to stop its development. Mayo researchers are exploring use of an agent that mimics heparin and inhibits SULF2. They are also examining whether preventing heparin sulfate synthesis would inhibit tumor growth.

If something has a very broad effect on signaling by growth factors, it may lead to an effective treatment, says Jinping Lai, M.D., Ph.D., a Mayo oncology researcher and the lead author of the study. SULF2 has a number of characteristics that make it an attractive target, such as the fact that it is widely present in tumors. We are exploring a number of options with SULF2 as a focal point for treatment not only in liver cancer, but also in head and neck, pancreas, breast and other types of cancer.

The researchers hope to identify drugs that block SULF2, and seek to thoroughly understand the mechanisms involved, including the determination of what other growth signaling pathways are affected by SULF2. They are also looking further at GPC3 as a potential biomarker for liver cancer or as a possible therapeutic target.

In 2007, Dr. Lai presented information at the annual meeting of the American Association for Cancer Research on the role of SULF2 in survival of patients with head and neck cancer -- the first concrete link to survival of patients with a specific tumor type.


'/>"/>

Contact: Elizabeth Zimmermann
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Radiologists encouraged to look beyond cancer for clinically unseen diseases
3. Clinical depression linked to abnormal emotional brain circuits
4. Preclinical study suggests organ-transplant drug may aid in lupus fight
5. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
6. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
7. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
8. MinuteClinic Becomes Participating Provider with Assurant Health
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Acupuncturists Relocation Tightens Relationship With Fertility Clinic
11. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... It’s that time of year when most people have ... Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and Garrison Forest School ... aside. , That’s why one of her first decisions when her IAAM two-year presidency ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... recover after a disaster, announced today the acquisition of Hawaii DKI. Hawaii DKI ... , “Investing in like-minded companies who excel at service and response helps ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study from the ... Medicare rates for a variety of medical services in Illinois as of 2015. ... 2015 Fee Schedule Rates in Illinois, are professional medical services, hospital outpatient ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty ... continuation of the ‘Pay It Forward’ program into 2016. BioPlus partners with several ... specialty pharmacy. , “Since our Pay It Forward program began, we are ...
(Date:2/9/2016)... (PRWEB) , ... February 10, 2016 , ... The ... the need to “level the playing field .” , As corresponding author Dr John ... we use to categorize and diagnose our chronic pain patients. ‘Chronic cancer pain’ ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... -- This TforG report includes the Surgical Procedures Database ... system in South Korea . To ... provides written and numerical analysis on the current trends, ... the latest reforms of the local Healthcare system are ... The report helps businesses gain a unique insight ...
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson ... Capital Markets Global Healthcare Conference on Tuesday, Feb. 23, ... Dominic Caruso , Vice President, Finance & Chief ... Consumer will represent the Company in a session scheduled ... . --> www.investor.jnj.com . --> ...
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
Breaking Medicine Technology: